Silexion Therapeutics Corp SEC Filings

Silexion Therapeutics Corp is a Cayman Islands clinical-stage biotech focused on RNAi silencing of KRAS for KRAS G12D/V locally advanced pancreatic cancer. Their lead candidate, SIL204, is a second-generation siRNA delivered intratumorally plus subcutaneous systemic dosing alongside standard-of-care chemotherapy. The company completed a public offering on September 12, 2025 raising approximately $6.0 million gross and holds an At-The-Market sales agreement to offer up to $13.17 million of ordinary shares through H.C. Wainwright. As of June 30, 2025 pro forma cash was presented and pro forma shareholders’ equity increased after recent financings. Management plans toxicology studies in 2025 and regulatory submissions to support a planned Phase 2/3 randomized trial initiating in H1 2026.

Silexion Therapeutics Corp. received a Nasdaq Compliance Letter confirming it has met the Nasdaq Capital Market's shareholder equity requirement and minimum $1.00 bid price requirement. The company completed financings that increased pro forma shareholders' equity by $10.3 million to approximately $9.41 million as of September 15, 2025. After a 1-for-15 reverse share split effected July 29, 2025, the closing price of the ordinary shares has been above $1.00. Nasdaq will monitor the company via a mandatory panel monitor through September 23, 2026, and a future equity deficiency during that period could lead to a delist determination and a new hearing opportunity.

Silexion Therapeutics Corp Schedule 13D/A reports that Moringa-related parties disclosed ownership totaling approximately 14.6% of the company's ordinary shares. The filing states Silexion issued 450,000 ordinary shares to Moringa Sponsor, LP on September 15, 2025, in conversion of $1.8 million of an outstanding promissory note, but the Reporting Persons expressly dispute the validity of that issuance and do not concede beneficial ownership of those shares. The cover-page totals combine 6,970 issued ordinary shares, 372 ordinary shares underlying warrants and the 450,000 shares the Reporting Persons contest. The Reporting Persons also reported a pro rata distribution on August 7, 2025 of certain shares and warrants to limited partners.

The reporting persons—Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton—filed a Schedule 13G reporting beneficial ownership of 224,050 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K122), representing 9.9% of the class. The disclosed position consists of 106,250 ordinary shares and warrants (106,250 Series A-1 and 106,250 Series A-2) subject to conversion limits that cap aggregate beneficial ownership at 224,050 shares to prevent ownership above 9.99%. Lind Global Partners III LLC is the general partner of the fund and Jeff Easton is the managing member; each may be deemed to have sole voting and dispositive power over the reported shares. The filers certify the holdings were not acquired to change or influence control of the issuer.

Silexion Therapeutics Corp disclosed that three reporting persons—Intracoastal Capital, LLC, Mitchell P. Kopin and Daniel B. Asher—may each be deemed to beneficially own 244,771 ordinary shares, representing 9.99% of the class as of close of business on September 17, 2025. The filing explains these shares arise primarily from warrants issued under a Securities Purchase Agreement and notes multiple warrants include blocker provisions that limit exercise to prevent ownership above 9.99% (and 4.99% for one warrant). Voting and dispositive power over the 244,771 shares is reported as shared rather than sole.

Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.

Orca Capital AG disclosed ownership of 131,250 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K130), representing 6.2% of the outstanding class based on 2,123,892 shares after the issuer's registered offering. Orca reports sole voting and dispositive power over these shares. The filing notes Orca holds warrants for 262,500 additional shares but cannot exercise them to the extent doing so would increase its stake above a 4.99% blocker under the warrant terms. The statement affirms the position was not acquired to change or influence control of the issuer.

Lincoln Alternative Strategies LLC reported beneficial ownership of 131,250 ordinary shares of Silexion Therapeutics Corp., representing 6.18% of the outstanding common stock based on 2,123,892 shares outstanding as of September 12, 2025. The filing on Schedule 13G states the shares are held with sole voting and dispositive power and that they were not acquired to change or influence control of the issuer. The report lists the filers Delaware organization, principal address in Miami Beach, FL, and is signed by Stephen Temes as Managing Member on September 15, 2025.